Epidermal growth factor inhibition in solid tumours.

about

Therapeutic options to target angiogenesis in human malignancies.Epidermal growth factor receptor signaling in nonsmall cell lung cancer.Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer.

P2860

Q36634261-4506E567-7FE1-4CCA-89A7-2204589FB0C9 Q39752055-FA68A7CE-65C1-4E11-8E07-AC5E553E048A Q42660638-43480009-83F1-4BAA-94C0-12745EFBE526

P2860

Epidermal growth factor inhibition in solid tumours.

Item

http://www.wikidata.org/entity/Q36239648

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Epidermal growth factor inhibition in solid tumours.

@ast

Epidermal growth factor inhibition in solid tumours.

@en

type

Item

label

Epidermal growth factor inhibition in solid tumours.

@ast

Epidermal growth factor inhibition in solid tumours.

@en

prefLabel

Epidermal growth factor inhibition in solid tumours.

@ast

Epidermal growth factor inhibition in solid tumours.

@en

P1476

Epidermal growth factor inhibition in solid tumours.

@en

P2093

Anil Potti

http://www.w3.org/2001/XMLSchema#string

Apar Kishor Ganti

http://www.w3.org/2001/XMLSchema#string

P2860

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt.

Molecular determinants of cetuximab efficacy.

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.

The epidermal growth factor receptor and its inhibition in cancer therapy.

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.

ErbB-targeted therapeutic approaches in human cancer.

P304

1165-1174

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.5.9.1165

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16120047

http://www.w3.org/2001/XMLSchema#string

Epidermal growth factor inhibition in solid tumours.

about

P2860

P2860

Epidermal growth factor inhibition in solid tumours.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698